Key Points
- COO David Howton sold 4,932 shares on Dec. 3 at an average price of $5.11 for $25,202.52, trimming his stake by 13.03% to 32,908 shares; the sale was disclosed in an SEC filing.
- Stock snapshot: SLDB recently traded near $5.95, with a 12‑month range of $2.41–$7.37, a market cap of ~$463.2M, a negative P/E, and 50/200‑day moving averages around $5.3.
- Analyst and institutional picture: Analysts are mixed but the consensus is a "Moderate Buy" with a $14.82 target, even as some firms cut targets, and institutional holders own about 81.46% of the shares with several funds materially increasing positions.
Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CTO Paul Herzich sold 2,701 shares of the firm's stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $5.11, for a total value of $13,802.11. Following the transaction, the chief technology officer owned 26,622 shares in the company, valued at $136,038.42. This trade represents a 9.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Solid Biosciences Stock Down 1.5%
SLDB stock traded down $0.09 during trading on Friday, hitting $5.83. 547,960 shares of the company's stock traded hands, compared to its average volume of 1,650,216. The stock has a market capitalization of $454.45 million, a price-to-earnings ratio of -2.34 and a beta of 2.97. Solid Biosciences Inc. has a 52 week low of $2.41 and a 52 week high of $7.37. The stock has a fifty day moving average price of $5.34 and a two-hundred day moving average price of $5.26.
Solid Biosciences (NASDAQ:SLDB - Get Free Report) last issued its earnings results on Monday, November 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.06). As a group, equities research analysts expect that Solid Biosciences Inc. will post -2.84 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts have weighed in on SLDB shares. Wedbush dropped their target price on Solid Biosciences from $17.00 to $14.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 13th. Needham & Company LLC began coverage on Solid Biosciences in a research report on Thursday. They issued a "buy" rating and a $16.00 target price on the stock. Barclays set a $9.00 price target on Solid Biosciences and gave the stock an "overweight" rating in a research note on Tuesday, November 4th. Weiss Ratings restated a "sell (d-)" rating on shares of Solid Biosciences in a research note on Wednesday, October 8th. Finally, Chardan Capital reissued a "buy" rating and set a $15.00 target price on shares of Solid Biosciences in a research note on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $14.82.
Check Out Our Latest Stock Analysis on SLDB
Hedge Funds Weigh In On Solid Biosciences
Several hedge funds have recently made changes to their positions in SLDB. XTX Topco Ltd acquired a new stake in Solid Biosciences during the first quarter valued at approximately $151,000. Charles Schwab Investment Management Inc. raised its position in shares of Solid Biosciences by 8.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 68,607 shares of the company's stock worth $254,000 after purchasing an additional 5,220 shares during the period. Invesco Ltd. lifted its holdings in shares of Solid Biosciences by 228.3% during the first quarter. Invesco Ltd. now owns 40,180 shares of the company's stock valued at $149,000 after purchasing an additional 27,943 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Solid Biosciences in the 1st quarter valued at $95,000. Finally, Nuveen LLC purchased a new position in Solid Biosciences in the 1st quarter worth about $161,000. Institutional investors and hedge funds own 81.46% of the company's stock.
About Solid Biosciences
(
Get Free Report)
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
